Cross-Border Enrollment

Discover how Ergomed facilitated access to a Phase II/III Clinical Trial for Primary Hyperoxaluria (PH), an ultra-rare metabolic disorder, by ensuring a 5-year-old refugee patient from North Africa could participate in the study from Barcelona.

This case study highlights Ergomed’s coordinated efforts in overcoming logistical and language barriers, including translation, interpretation, and direct-to-home medication delivery. Download the full case study to learn how Ergomed’s tailored solutions make cross-border trials accessible and patient-centered, supporting success in rare disease research.

Please fill out the form to view the content

"*" indicates required fields

Please enter your details to get access to the resource

First Name*

Last Name*

Job Title

Industry*

Company*

Email*

Telephone

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.

Phone

This field is for validation purposes and should be left unchanged.

Enter a term to search

Cross-Border Enrollment: Breaking Barriers for Treatment

Discover how Ergomed facilitated access to a Phase II/III Clinical Trial for Primary Hyperoxaluria (PH), an ultra-rare metabolic disorder, by ensuring a 5-year-old refugee patient from North Africa could participate in the study from Barcelona.

Please fill out the form to view the content

Please enter your details to get access to the resource